^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    2d
    Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis (clinicaltrials.gov)
    P1, N=23, Terminated, Xencor, Inc. | N=128 --> 23 | Active, not recruiting --> Terminated; Business Decision
    Enrollment change • Trial termination
    2d
    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov)
    P1, N=36, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Site plans to become a site for a multicenter study of this therapy
    Trial termination • IO biomarker
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Zuplenz (ondansetron oral dispersible film)
    4d
    Machine learning-based identification of core regulatory genes in hepatocellular carcinoma: insights from lactylation modification and liver regeneration-related genes. (PubMed, Front Oncol)
    We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC.
    Journal
    |
    CD8 (cluster of differentiation 8) • CCNA2 (Cyclin A2) • KIF2C (Kinesin Family Member 2C) • RACGAP1 (Rac GTPase activating protein 1)
    |
    GS-4528
    9d
    First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma. (PubMed, medRxiv)
    Dose-dependent CTLA-4 receptor upregulation was observed on CD8+ and CD4+ T cells, whereas PD-1 and TIM-3, remained unchanged. In patients with HGSOC, AVB-001 is safe and effectively activates cytotoxic T cells, supporting further investigation of this locoregional immunotherapy.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    AVB-001
    10d
    Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    14d
    Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer (clinicaltrials.gov)
    P2, N=27, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    14d
    Phase I Study of HM16390 as a Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=292, Recruiting, Hanmi Pharmaceutical Company Limited | N=215 --> 292 | Trial completion date: Mar 2030 --> Jul 2031 | Trial primary completion date: Mar 2030 --> Jul 2031
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • HM16390
    17d
    Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors. (PubMed, Clin Cancer Res)
    The safety profile of this combination was manageable. Prominent pharmacodynamic effects were elucidated; antitumor activity was limited.
    Journal • PD(L)-1 Biomarker
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • CRP (C-reactive protein)
    |
    Tecentriq (atezolizumab) • Gazyva (obinutuzumab) • cergutuzumab amunaleukin (RG7813)
    20d
    L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    21d
    L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    22d
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    24d
    Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=8, Terminated, Alaunos Therapeutics | N=180 --> 8 | Active, not recruiting --> Terminated; Funding
    Enrollment change • Trial termination • IO biomarker
    |
    Proleukin (aldesleukin)